Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 535

Results For "SSI"

5498 News Found

Carbon-based non-toxic and reusable wrapper to increase shelf life of fruits
Sustainability | August 09, 2021

Carbon-based non-toxic and reusable wrapper to increase shelf life of fruits

This work has been published in the journal ‘ACS applied materials and interface’


India's doctor-population ratio to reach WHO benchmark soon: Dr Vinod Paul
Healthcare | August 09, 2021

India's doctor-population ratio to reach WHO benchmark soon: Dr Vinod Paul

By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas


Centre releases Rs. 60 crore to states seeking grants to tackle the Sickle Cell Anaemia
Policy | August 09, 2021

Centre releases Rs. 60 crore to states seeking grants to tackle the Sickle Cell Anaemia

Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease


Metropolis Healthcare PAT at Rs 74.89 crores for Q1FY22
Healthcare | August 08, 2021

Metropolis Healthcare PAT at Rs 74.89 crores for Q1FY22

Board approves fundraise of Rs 1500 crore


Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr
Biotech | August 08, 2021

Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr

The company expects revenue growth of 10-15 per cent in the US


TAKE divests stake in Navitas Life Sciences to HIG
Biotech | August 08, 2021

TAKE divests stake in Navitas Life Sciences to HIG

The transaction is expected to close in the Q4FY22


We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals
interviews | August 07, 2021

We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals

India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.


Stelis Biopharma appoints Mark W. Womack as CEO
People | August 07, 2021

Stelis Biopharma appoints Mark W. Womack as CEO

He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations


Mark W. Womack is the new CEO of Stelis Biopharma
Biotech | August 06, 2021

Mark W. Womack is the new CEO of Stelis Biopharma

He will be stationed at the company HQ in Bengaluru, India


Govt augments PSEs and Bharat Biotech to ramp up Covaxin production
Policy | August 06, 2021

Govt augments PSEs and Bharat Biotech to ramp up Covaxin production

CDSCO to fast-track trials and approval for COVID19 vaccine